Drug
A4250
A4250 is a pharmaceutical drug with 4 clinical trials. Historical success rate of 75.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
75.0%
Based on 3 completed trials
Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(25%)
Phase Distribution
Ph phase_1
2
50%
Ph phase_2
2
50%
Phase Distribution
2
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
2(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
75.0%
3 of 4 finished
Non-Completion Rate
25.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(3)
Terminated(1)
Detailed Status
Completed3
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
75.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (50.0%)
Phase 22 (50.0%)
Trials by Status
terminated125%
completed375%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_2
A4250, an IBAT Inhibitor in Pediatric Cholestasis
NCT02630875
completedphase_1
A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384
NCT02963077
completedphase_1
Study of A4250 in Healthy Volunteers Under Fasting, Fed and Sprinkled Conditions
NCT03608319
terminatedphase_2
IBAT Inhibitor A4250 for Cholestatic Pruritus
NCT02360852
Clinical Trials (4)
Showing 4 of 4 trials
NCT02630875Phase 2
A4250, an IBAT Inhibitor in Pediatric Cholestasis
NCT02963077Phase 1
A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384
NCT03608319Phase 1
Study of A4250 in Healthy Volunteers Under Fasting, Fed and Sprinkled Conditions
NCT02360852Phase 2
IBAT Inhibitor A4250 for Cholestatic Pruritus
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4